GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group A/S (OCSE:PEG) » Definitions » Cyclically Adjusted Price-to-FCF

Pharma Equity Group A/S (OCSE:PEG) Cyclically Adjusted Price-to-FCF : (As of Jun. 13, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group A/S Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pharma Equity Group A/S Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Pharma Equity Group A/S's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group A/S Cyclically Adjusted Price-to-FCF Chart

Pharma Equity Group A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pharma Equity Group A/S Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pharma Equity Group A/S's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Pharma Equity Group A/S's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group A/S's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group A/S's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group A/S's Cyclically Adjusted Price-to-FCF falls into.



Pharma Equity Group A/S Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Pharma Equity Group A/S's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Pharma Equity Group A/S's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.008/118.4000*118.4000
=-0.008

Current CPI (Mar. 2024) = 118.4000.

Pharma Equity Group A/S Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201106 -2.794 96.100 -3.442
201109 -2.319 96.300 -2.851
201112 -1.057 96.300 -1.300
201203 0.461 98.300 0.555
201206 -8.187 98.200 -9.871
201209 -14.815 98.700 -17.772
201212 10.052 98.300 12.107
201303 -0.350 99.300 -0.417
201306 -0.732 99.100 -0.875
201309 -2.130 99.200 -2.542
201312 -0.406 99.000 -0.486
201403 1.102 99.600 1.310
201406 -0.760 99.700 -0.903
201409 -0.368 99.700 -0.437
201412 -1.793 99.400 -2.136
201503 0.000 100.200 0.000
201506 -0.004 100.300 -0.005
201509 -0.188 100.200 -0.222
201512 0.040 99.800 0.047
201603 -0.009 100.200 -0.011
201606 -0.008 100.600 -0.009
201612 0.000 100.300 0.000
201706 0.000 101.200 0.000
201712 0.000 101.300 0.000
201806 0.000 102.300 0.000
201812 0.000 102.100 0.000
201906 0.000 102.900 0.000
201912 0.000 102.900 0.000
202006 0.000 103.200 0.000
202012 0.000 103.400 0.000
202106 0.000 105.000 0.000
202112 0.000 106.600 0.000
202206 0.000 113.600 0.000
202209 0.000 116.400 0.000
202212 0.000 115.900 0.000
202303 -0.004 117.300 -0.004
202306 -0.006 116.400 -0.006
202309 -0.003 117.400 -0.003
202312 -0.003 116.700 -0.003
202403 -0.008 118.400 -0.008

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pharma Equity Group A/S  (OCSE:PEG) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Pharma Equity Group A/S Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group A/S's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Equity Group A/S (OCSE:PEG) Business Description

Traded in Other Exchanges
N/A
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develops technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement.